Status:
COMPLETED
Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Lead Sponsor:
Northern Italy Leukemia Group
Conditions:
Hypereosinophilic Syndrome
Chronic Eosinophilic Leukemia
Eligibility:
All Genders
15+ years
Phase:
PHASE2
Brief Summary
The study was performed to assess: 1) clinical activity of Imatinib in patients with HES, CEL and CIH; 2) correlation between Imatinib activity and specific disease subtype; 3) long-term outcome of HE...
Detailed Description
Hypereosinophilic syndrome (HES), chronic eosinophilic leukaemia (CEL) and chronic idiopathic hypereosinophilia (CIH) are rare disorders characterized by chronic hypereosinophilia with possible damage...
Eligibility Criteria
Inclusion
- patients with a diagnosis of HES, CEL and CIH, who are either previously untreated or have been treated with corticosteroids, cytotoxic drugs, and IFN.
- age \> 15 years.
- signature of a written informed consent(by parents/tutors for patients aged \< 18 years).
Exclusion
- patients with a diagnosis of secondary hypereosinophilia
- age \< 15 years
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00787384
Start Date
October 1 2004
End Date
December 1 2007
Last Update
December 29 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
USC Ematologia Ospedali Riuniti di Bergamo
Bergamo, Bergamo, Italy, 24128
2
Divisione di Ematologia Spedali Civili di Brescia
Brescia, Brescia, Italy
3
USC Ematologia Azienda Ospedaliera Università Careggi
Florence, Firenze, Italy, 50134
4
UO Ematologia, Azienda Ospedaliera ULSS6
Vicenza, Vicenza, Italy, 36100